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Supplementary data:
Mandatory dose decreases or interruptions for hematological toxicity:
There are mandatory dose decreases or interruptions for declining platelet count or ANC level while on ruxolitinib therapy. Dosing must be held if platelet count decline below 25 x 109 /L, or if ANC falls below 0.5 x 109 /L. Patients with platelets below 50 x 109 /L and/or ANC below 0.5 x 109 /L should be followed biweekly. The dose reduction strategy for platelet count is depicted in Table 1 This table takes into account doses that might be present after a prior dose reduction. Ruxolitinib dose will not be adapted to lymphocytes count. Restarting or re-instituting previous dose Dosing may be restarted following recovery of platelet count and/or ANC to acceptable levels. ANC level recovery to above 500/µL but less than 750/µL will allow dosing to be restarted at 5 mg BID. ANC level between 750 and 1000/µL may restart at 10 mg BID. Increase of ANC above 1000/µL will allow a further dose increase to the initial dosing (15 mg BID or 20 mg BID). If the study drug is interrupted for any reason for more than 4 weeks, dosing may not be restarted. Study drug must be permanently discontinued if the lowest allowed dose (5 mg BID, or 5 mg QD with concomitant CYP3A4 inhibitor) is not tolerated due to the following: platelet count cannot be maintained > 25 x 109 /L, ANC cannot be maintained > 0.5 x 109 /L. Study drug must also be permanently discontinued due to the following: > grade 3 clinical event after re-challenge with the drug. Exceptions NOT requiring study withdrawal are fatigue, insomnia, obesity, constitutional symptoms (disabling but not life-threatening), salivary gland changes, arthritis, and joint effusion. Concentra'on (pg/mL) PDGF-BB concentration in patients with (n=8) or without (n=17) pruritus before treatment (-) and after one cycle of ruxolitinib (+).
